drugset / Trial / NCT07149649

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07149649 ↗

Phase 2/3 Recruiting 230 enrolled Swiss Cancer Institute
RandomizedParallel-groupTriple-blindTreatment

Summary

This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes. Magnesium is important for immune function, and low levels during chemotherapy are common. Participants are randomly assigned to receive either magnesium or a placebo, both as infusions and tablets. Neither the participants nor the doctors know who receives which treatment. The study compares the two groups to see if magnesium helps and how well it is tolerated.

Timeline

Start
2026-08
Primary completion
2031-01-01
Completion
2035-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesiocard Unknown 2.5 mmol Oral
Subject Magnesium Diasporal Small molecule 4 mmol Intravenous